Mustang Bio, Nationwide Children's Hospital partner to develop C134
Mustang Bio and Nationwide Children's Hospital announced that they have partnered and entered into an exclusive worldwide license agreement to develop an oncolytic virus, or C134, for the treatment of glioblastoma multiforme. A Phase 1 clinical trial evaluating C134, an attenuated herpes simplex virus type 1, or HSV-1, in recurrent glioblastoma multiforme is being conducted at the University of Alabama at Birmingham. The trial is led by James Markert chairman of the Department of Neurosurgery at UAB, who developed C134 in collaboration with Kevin Cassady associate professor of pediatrics at Nationwide Children's Hospital. C134 is a second-generation HSV-1 oncolytic virus that has improved replication in tumors in murine models, but with the same toxicity profile as its first-generation predecessors. In these preclinical studies, it not only demonstrates direct anti-tumor activity, but also elicits an immune response that can reverse tumor-associated immunosuppression. Subsequent clinical trials will investigate a combination treatment of MB-101 and C134. These trials are supported by preclinical studies that have appeared to demonstrate the synergistic potential of an oncolytic virus, which can induce an anti-tumor immune response when combined with CAR-T therapy to target solid tumors.